Table 3

Multivariate analysis by logistic regression with clinical and paraclinical data

VariablesOR (95% CI)P value of the variable*P value of the overall model*AUC of ROC curve analysis (95% CI)
Anti-FGFR3-positive patients (n=65) versus all anti-FGFR3-negative patients (n=361) (demographic and initial mandatory data)
 Age1.03 (1.00 to 1.05) 0.02 < 0.001 0.68
(0.63 to 0.73)
 Autoimmune context1.36 (0.72 to 2.59)0.34
 Country (Brazil)7.3 (3.0 to 18.0) < 0.001
 Sex (M)0.89 (0.49 to 1.61)0.70
 SNN score0.93 (0.86 to 1.01)0.10
Anti-FGFR3-positive patients (n=65) versus anti-FGFR3-negative patients (n=66) (clinical data at last clinical exam)
 Age at onset1.03 (0.99 to 1.08)0.06 < 0.001 0.82
(0.73 to 0.89)
 Sex (M)0.64 (0.24 to 1.74)0.39
 Country (Brazil)3.89 (0.58 to 0.94)0.16
 Topography: distal LL3.65 (0.69 to 19.4)0.13
 Topography: trunk0.19 (0.04 to 0.94) 0.04
 Clinical signs: PTS and DSS alteration0.22 (0.07 to 0.77) 0.02
 Symptoms: paresthesia4.90 (1.24 to 19.3) 0.02
 N abnormal SNAPs >50% LLN in UL1.63 (1.02 to 2.60) 0.04
 N abnormal SNAPs in LL1.68 (1.11 to 2.54) 0.01
Anti-FGFR3-positive Brazilian SNN patients (n=15) versus anti-FGFR3-positive European SNN patients (n=27) (clinical data at first exam)
 Age at onset0.83 (0.68 to 1.01)0.07 < 0.001 0.98
(0.87 to 0.99)
 Sex (M)0.57 (0.03 to 10.7)0.70
 Topography: proximal UL23.1 (1.3 to 409) 0.03
 Topography: asymmetry169 (3.4 to 8424) 0.01
Anti-FGFR3-positive Brazilian SNN patients (n=15) versus anti-FGFR3-positive European SNN patients (n=27) (clinical data at last exam)
 Age at onset0.72 (0.54 to 0.96) 0.02 < 0.001 0.97
(0.85 to 0.99)
 Sex (M)2.04 (0.14 to 29.3)0.60
 Topography: asymmetry1038 (5.4 to 1 97 867) 0.009
  • *The bolded p values are statistically significant (≤0.05).

  • ANA, antinuclear antibody; AUC, area under the curve; DSS, deep and superficial sensation (myelinated sensory fibres);FGFR3, fibroblast growth factor receptor 3; LL, lower limbs; LLN, lower limit of the normal; N, number; PTS, pain and temperature sensation (unmyelinated sensory fibres); ROC, receiver operating characteristic; SNAPs, sensory nerve action potentials; SNN, sensory neuronopathy; UL, upper limbs.